Table of Contents
ISRN Oncology
Volume 2011, Article ID 303128, 5 pages
Review Article

Controversies in the Management of Papillary Thyroid Cancer Revisited

1Department of Surgery, University of Arizona, 1501 N. Campbell Avenue, P.O. Box 245131, Tucson, AZ 85724, USA
2Department of Surgery, University of California, San Francisco, CA 94143, USA

Received 1 July 2011; Accepted 21 July 2011

Academic Editors: A. Berner, A. E. Bilsland, and A. Celetti

Copyright © 2011 Marlon A. Guerrero and Orlo H. Clark. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


The debate on the appropriate treatment of patients with papillary thyroid cancer (PTC) has persisted for several decades. The main controversies focus on the extent of surgery, the timing of central neck dissection, and the indications for radioactive iodine ablation. These controversies continue, for the most part, due to the good prognosis of PTC patients and the questionable effect these treatment modalities have on patient survival. This paper addresses these three controversies and the role of molecular tumor markers in the appropriate treatment selection.